Transforming Patient Access to Innovative Therapies
In a significant move to enhance the accessibility of innovative treatments, myTomorrows has successfully raised $29 million in financing. This funding, backed by Avego, aims to expand myTomorrows’ global footprint and accelerate the advancement of AI innovations in healthcare. The investment will also strengthen partnerships within the industry, facilitating a broader reach in patient care.
MyTomorrows’ Commitment to Bridging Treatment Gaps
Currently, more than 300 million patients worldwide are confronted with conditions that lack approved treatment options. Moreover, there are over 10,000 therapies either in development or pending approval. myTomorrows thrives on this pressing healthcare challenge by connecting patients with pre-approval treatments, including opportunities for clinical trials and expanded access programs (EAPs).
The recent financial influx is set to fast-track myTomorrows’ international growth, further enhancing its AI-driven platform designed to connect physicians, patients, trial sites, and BioPharma partners seamlessly. This platform strives to optimize accessibility and insights into treatment options, while also fostering collaborations with industry partners aimed at reducing clinical development timelines.
Insights from the Leadership
Michel van Harten, the CEO of myTomorrows, expressed the transformative potential of this investment: "This marks a pivotal step in our journey to ensure that every patient has a fair opportunity to access tomorrow's therapies, regardless of location." He highlighted that Avego's extensive life sciences expertise, especially within the BioPharma sector, is crucial for scaling their platform and amplifying their global impact.
James Flexner, Managing Partner of Avego, also acknowledged the importance of this collaboration, stating, "We support myTomorrows in its mission to revolutionize patient access to therapies in development. Their unique position will help eliminate barriers for both patients and providers while reinforcing their role as a vital partner to BioPharma companies."
Innovative Solutions for Global Patient Needs
Founded in 2012, myTomorrows was born out of a vision to create better connections between patients and promising therapies. With this latest funding, the company is ready to enter a new phase characterized by rapid growth and significant global impact.
The company has introduced the world’s most comprehensive AI-powered platform for pre-approval treatments, successfully aiding over 16,900 patients in accessing therapies across more than 133 countries. MyTomorrows offers essential navigation services, treatment matching, and improved access to clinical trials and EAPs, proving its commitment to enhancing patient experience.
For BioPharma partnerships, myTomorrows provides strategic solutions for clinical trial recruitment and expanded access while offering real-world data collection capabilities. Additionally, trial sites benefit from a cohesive referral management system that not only elevates trial visibility but also ensures up-to-date status information.
A Vision for the Future of Treatment Access
As the primary gateway for pre-approval therapies, myTomorrows is laying the groundwork for a new era in treatment access, characterized by AI-enhanced transformation, adaptive regulations, and informed patients actively engaged in their healthcare.
Through a robust integration within global healthcare systems, their platform ensures that emerging therapies reach the patients who need them most, precisely when they are needed.
About myTomorrows
myTomorrows stands out as a pioneering global HealthTech company dedicated to connecting patients, physicians, trial sites, and BioPharma partners. This endeavor fosters faster and improved access to pre-approval treatments. By harnessing a centralized platform powered by AI-driven insights and human expertise, myTomorrows tackles some of the significant barriers patients face in accessing healthcare.
Operating from Amsterdam with a branch in New York City, myTomorrows has proudly supported over 16,900 patients and 2,800 physicians across more than 340 sites in over 133 nations.
Frequently Asked Questions
What does myTomorrows focus on?
myTomorrows connects patients with innovative pre-approval treatments, enhancing access to clinical trials and therapies awaiting approval.
What is the significance of the recent funding?
The $29 million funding from Avego will enable myTomorrows to expand its global reach and enhance its AI-driven platform for improved patient access.
How does myTomorrows support patients in need?
MyTomorrows provides expert navigation services, treatment matching, and simplifies access to clinical trials and expanded access programs for patients.
How many patients has myTomorrows helped?
To date, myTomorrows has assisted over 16,900 patients across more than 133 countries worldwide.
What industry partnerships does myTomorrows foster?
MyTomorrows collaborates with BioPharma companies, providing solutions for clinical trial recruitment and real-world data collection to expedite the therapeutic landscape.
